Initial data for the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in second quarter of 2025 Dosing in the Heart-2 trial has moved to the 0.6 mg/kg cohort VERVE-301 nominated ...
The PCSK9 inhibitor evolocumab (Repatha) got the FDA's blessing for cardiovascular protection, with or without a history of cardiovascular disease (CVD). Evolocumab is now indicated for the wider pool ...
Often people think their risk of heart disease and other cardiovascular diseases is tied up with their total cholesterol ...
Verve Therapeutics focuses on gene editing technology for one-dose therapies to reduce lipid levels related to ASCVD. VERV's pipeline includes therapies targeting genes like PCSK9, ANGPTL3, and LPA to ...
A new case-control genetic study is reassuring in finding no association between a genetic proxy for pharmacologic PCSK9 inhibition and either heart failure or adverse cardiac remodeling in a large ...
A new study led by Baylor College of Medicine and presented at the American College of Cardiology’s Annual Scientific Session together with World Congress of Cardiology found that an oral PCSK9 ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A once-daily oral PCSK9 inhibitor reduced LDL in ...
Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. PCSK9 inhibitors may best be known for their powerful LDL-lowering effects but are less appreciated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback